KIT and acute myeloid leukemia: Frequencies of ICM-expressing TCD3+ cells (e.g., TCD3+CTLA4+/TCD3+, TCD3+PD1+/TCD3+, TCD3+TIGIT+/TCD3+) were significantly downregulated after MLC with Kit M-pretreated vs. not pretreated AML patients’ and healthy donors’ samples (Figure 3).